Takuma Irie
Overview
Explore the profile of Takuma Irie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, et al.
Nat Cancer
. 2025 Feb;
PMID: 39972105
Platinum-based definitive chemoradiotherapy (dCRT) is the standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) that invades the aorta, vertebral body or trachea; however, complete response...
2.
Nishinakamura H, Shinya S, Irie T, Sakihama S, Naito T, Watanabe K, et al.
Sci Transl Med
. 2025 Feb;
17(785):eadk3160.
PMID: 39937883
Immune checkpoint blockade therapy has been successfully applied in clinical settings as a standard therapy for many cancer types, but its clinical efficacy is restricted to patients with immunologically hot...
3.
Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin Y, et al.
Sci Immunol
. 2022 Oct;
7(76):eabk0957.
PMID: 36206353
Regulatory T (T) cells suppress effective antitumor immunity in tumor-bearing hosts, thereby becoming promising targets in cancer immunotherapy. Despite the importance of T cells in tumor immunity, little is known...
4.
Itahashi K, Irie T, Nishikawa H
Eur J Immunol
. 2022 Jul;
52(8):1216-1227.
PMID: 35879813
Regulatory T (Treg) cells are required for maintaining self-tolerance and preventing the development of autoimmune diseases. However, Treg cells are abundant in tumors and suppress antitumor immunity, contributing to tumor...
5.
Masuhiro K, Tamiya M, Fujimoto K, Koyama S, Naito Y, Osa A, et al.
JCI Insight
. 2022 Apr;
7(9).
PMID: 35389889
Bronchoalveolar lavage is commonly performed to assess inflammation and identify responsible pathogens in lung diseases. Findings from bronchoalveolar lavage might be used to evaluate the immune profile of the lung...
6.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, et al.
Cell Rep
. 2022 Feb;
38(5):110331.
PMID: 35108529
PD-1 blockade exerts clinical efficacy against various types of cancer by reinvigorating T cells that directly attack tumor cells (tumor-specific T cells) in the tumor microenvironment (TME), and tumor-infiltrating lymphocytes...
7.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin Y, Togashi Y, et al.
Cancer Cell
. 2022 Jan;
40(2):201-218.e9.
PMID: 35090594
The balance of programmed death-1 (PD-1)-expressing CD8 T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition...
8.
Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, et al.
Nat Commun
. 2021 Dec;
12(1):7280.
PMID: 34907192
Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are distinguished by high expression levels of the...
9.
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, et al.
Sci Immunol
. 2021 Nov;
6(65):eabc6424.
PMID: 34767457
PD-1 blockade exerts antitumor effects by reinvigorating tumor antigen–specific CD8 T cells. Whereas neoantigens arising from gene alterations in cancer cells comprise critical tumor antigens in antitumor immunity, a subset...
10.
Inamori K, Togashi Y, Fukuoka S, Akagi K, Ogasawara K, Irie T, et al.
JCI Insight
. 2021 Mar;
6(9).
PMID: 33755600
Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T...